BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18178448)

  • 1. Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors.
    Chen J; Linder KE; Cagnolini A; Metcalfe E; Raju N; Tweedle MF; Swenson RE
    Appl Radiat Isot; 2008 Apr; 66(4):497-505. PubMed ID: 18178448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation of a 177Hf complex formed by beta-decay of a 177Lu-labeled radiotherapeutic compound and NMR structural elucidation of the ligand and its Lu and Hf complexes.
    Cagnolini A; D'Amelio N; Metcalfe E; Nguyen HD; Aime S; Swenson RE; Linder KE
    Inorg Chem; 2009 Apr; 48(7):3114-24. PubMed ID: 19243162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
    Lantry LE; Cappelletti E; Maddalena ME; Fox JS; Feng W; Chen J; Thomas R; Eaton SM; Bogdan NJ; Arunachalam T; Reubi JC; Raju N; Metcalfe EC; Lattuada L; Linder KE; Swenson RE; Tweedle MF; Nunn AD
    J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites.
    Linder KE; Metcalfe E; Arunachalam T; Chen J; Eaton SM; Feng W; Fan H; Raju N; Cagnolini A; Lantry LE; Nunn AD; Swenson RE
    Bioconjug Chem; 2009 Jun; 20(6):1171-8. PubMed ID: 19480415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
    Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
    Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga-AMBA, and the synthesis and characterization of (nat)Ga-AMBA and [(67)Ga]Ga-AMBA.
    Cagnolini A; Chen J; Ramos K; Skedzielewski TM; Lantry LE; Nunn AD; Swenson RE; Linder KE
    Appl Radiat Isot; 2010 Dec; 68(12):2285-92. PubMed ID: 20638858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
    Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
    J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model.
    Liu IH; Chang CH; Ho CL; Chiu SP; Lee WC; Chang TJ; Chen LC; Wu YH; Chuang CH; Fu YK; Lee TW
    Anticancer Res; 2010 Oct; 30(10):4039-48. PubMed ID: 21036718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
    Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
    Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
    Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
    Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues.
    Thomas R; Chen J; Roudier MM; Vessella RL; Lantry LE; Nunn AD
    Clin Exp Metastasis; 2009; 26(2):105-19. PubMed ID: 18975117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of Lys¹(α,γ-Folate)Lys³(¹⁷⁷Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer.
    Aranda-Lara L; Ferro-Flores G; Azorín-Vega E; Ramírez FM; Jiménez-Mancilla N; Ocampo-García B; Santos-Cuevas C; Isaac-Olivé K
    Appl Radiat Isot; 2016 Jan; 107():214-219. PubMed ID: 26545016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs.
    de Blois E; Chan HS; de Zanger R; Konijnenberg M; Breeman WA
    Appl Radiat Isot; 2014 Feb; 85():28-33. PubMed ID: 24365877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.
    Johnson CV; Shelton T; Smith CJ; Ma L; Perry MC; Volkert WA; Hoffman TJ
    Cancer Biother Radiopharm; 2006 Apr; 21(2):155-66. PubMed ID: 16706636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints.
    Chakraborty S; Das T; Banerjee S; Sarma HD; Venkatesh M
    Nucl Med Commun; 2006 Aug; 27(8):661-8. PubMed ID: 16829766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaerobic 90Y- and 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist.
    Liu S; Harris TD; Ellars CE; Edwards DS
    Bioconjug Chem; 2003; 14(5):1030-7. PubMed ID: 13129408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical.
    Ghosh A; Woolum K; Kothandaraman S; Tweedle MF; Kumar K
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31398865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.
    Sosabowski JK; Lee M; Dekker BA; Simmons BP; Singh S; Beresford H; Hagan SA; McKenzie AJ; Mather SJ; Watson SA
    Eur J Pharm Sci; 2007 Jun; 31(2):102-11. PubMed ID: 17387005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target burn-up corrected specific activity of 177Lu produced via 176Lu(n, gamma) 177Lu nuclear reactions.
    Zhernosekov KP; Perego RC; Dvorakova Z; Henkelmann R; Türler A
    Appl Radiat Isot; 2008 Sep; 66(9):1218-20. PubMed ID: 18359234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131.
    De Decker M; Turner JH
    Cancer Biother Radiopharm; 2012 Feb; 27(1):72-6. PubMed ID: 22149590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.